Thanks to booming sales of blockbuster obesity and diabetes treatments, the amount that Americans spent on prescription drugs this year is on track to surpass $1 trillion, according to a report ...

AbbVie gains attention as healthcare rotation highlights Skyrizi, Rinvoq, immunology growth, and portfolio strength beyond ...

AbbVie’s $10.9B Apogee deal strengthens immunology beyond Humira, adds Zumilokibart optionality, and may be undervalued. See ...

Immunology is AbbVie's primary core competency. While the pharmaceutical company has successfully transitioned patients from Humira to its newer blockbusters, Skyrizi and Rinvoq, the Apogee ...

AbbVie said on Monday it ⁠would ⁠buy Apogee Therapeutics for $10.9 billion, the ⁠company's largest buyout in more than five years, as it seeks to ​bolster its treatment pipeline for inflammatory ...

AbbVie said today it would buy biotech Apogee Therapeutics for $10.9 billion, in its largest buyout in more than five years to strengthen its next-gen immunology pipeline.

A multi-billion-dollar cash offer and a 60% premium are on the table as AbbVie nears its biggest buyout in seven years.

Adalimumab and tocilizumab demonstrate comparable efficacy and safety as corticosteroid-sparing treatments for active refractory noninfectious uveitis, while anakinra is ineffective. Neither ...

Humira (adalimumab) is a biologic medication used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, and plaque psoriasis. For years, it has been one of ...

You helped me sign up for a Medicare Supplement Plan G and a Medicare Part D prescription drug plan; both plans started January 2021. These two plans have served me well so far. I just received ...

Dear Toni: I signed up for a supplemental Medicare Plan G and a Medicare Part D prescription drug plan, both of which started in January 2021. These two plans have served me well. I just received ...